AbbVie forecasts $3B run rate for Viekira Pak

On its 4Q14 earnings call on Friday, AbbVie Inc. (NYSE:ABBV) forecast that it would achieve a global annualized sales run rate of $3 billion for HCV drug regimen Viekira Pak paritaprevir/ ritonavir/ ombitasvir/ dasabuvir by YE15.

Approved Dec. 19, the drug has sparked a price war for exclusive formulary status with competitor Gilead Sciences Inc. (NASDAQ:GILD) and its HCV drugs Harvoni ledipasvir/ sofosbuvir and Sovaldi sofosbuvir. ...